Piper Jaffray downgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Neutral to Sell and reduces its price target from $13 to $5.
This article: 110 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE